Lyrokaul (lerodalcibep)

Where it stands

Lyrokaul (lerodalcibep), from LIB Therapeutics B.V., received a positive CHMP opinion on 2026-07-23. The records list its status as "Opinion" and show no approval date, so the European Commission (EC) has not yet granted marketing authorisation according to the data provided.

The recommended indication is for adults with primary hypercholesterolaemia (heterozygous familial (HeFH) and non-familial) or mixed dyslipidaemia as an adjunct to diet. The therapeutic areas are recorded as hypercholesterolemia and dyslipidemias.

The same substance is recorded as approved in the US under the name Lerochol. The records give no further detail on that approval, such as its date, label or conditions, so no comparison of US and EU indications can be made from this data.

Regulatory pathway and designations

The records show no designations for this product. No orphan, PRIME, or similar designation is recorded, and nothing is stated about the type of marketing authorisation (for example standard or conditional) or the assessment timetable.

In general EU procedure, a positive CHMP opinion is a scientific recommendation. It becomes legally effective only when the EC adopts a decision, which normally takes up to 67 days. The records estimate the EC decision for 2026-09-28, calculated as the CHMP opinion date plus 67 days. This is explicitly flagged as an estimate and not an official date.

The product is listed under the name Lyrokaul in the EU and Lerochol in the US. The records do not explain the difference in names.

Safety and pharmacovigilance

The records do not include safety data, such as adverse reactions, contraindications, warnings, or risk management plan details. They also do not state whether additional monitoring or post-authorisation safety studies are required, so no safety assessment can be made here.

In general, when the EC authorises a medicine, the product information and risk management commitments set out in the CHMP opinion become binding conditions. The final product information should be reviewed once published to understand the safety profile and any pharmacovigilance obligations.

What to watch

The key near-term event is the EC decision, estimated for 2026-09-28. This date is an estimate based on the standard 67-day period, so the actual timing may differ. Confirmation of the authorisation and its date would update the "Opinion" status.

Once published, the EC decision and the product information should be checked to confirm that the authorised indication matches the CHMP-recommended wording, and to identify any conditions attached to the authorisation.

It would also be useful to compare the EU label with the US label for Lerochol once that information is available, since the records do not describe the US indication or conditions.